Gentiana macrophylla

Gentiana macrophylla (Qinjiao): A Comprehensive Reference

1. Identity, Botanical Classification, and Natural Source

Gentiana macrophylla Pall. is a perennial herbaceous plant belonging to the family Gentianaceae and the genus Gentiana. Radix Gentianae Macrophyllae, commonly known as Qinjiao (秦艽 in Chinese), is the dried root of medicinal plants that belong to the Gentianaceae family and Gentiana genus. The species name macrophylla refers to the plant's characteristically large leaves, and "Pall." denotes its formal description by the German naturalist Peter Simon Pallas. The full binomial name accepted in pharmacopoeial contexts is Gentiana macrophylla Pall.

Gentiana macrophylla Pall. is a perennial herb belonging to Radix Gentianae macrophyllae (Gentianaceae) and is found in the high alpine lands of the Tibetan Plateau at altitudes between 2400 and 3500 meters. Populations are also found across northwestern and northeastern China, particularly in Shaanxi, Gansu, and Shanxi provinces, as well as in parts of Inner Mongolia and Xinjiang. Both wild and cultivated specimens have been collected from the Qinling Mountains, China.

The medicinal part of the plant is its dried root. The species has faced significant conservation pressures: due to medicinal properties and considerable commercial interest, the distribution and number of wild G. macrophylla populations has become very limited due to overexploitation, and G. macrophylla is now listed on the National Key of Protected Wild Herbs in China.

Pharmacopoeial Classification and Related Species

In Chinese medicine, the drug name "Qinjiao" refers to a group of plants, not exclusively to G. macrophylla. In the Chinese Pharmacopoeia, the dried roots of four species from the genus Gentiana — including G. macrophylla, G. crassicaulis, G. straminea, and G. dahurica — are recorded and used as the raw materials of Gentianae Macrophyllae Radix ("Qin-Jiao" in Chinese). Of these, G. macrophylla Pall. is considered the primary botanical source. Since the Tang Dynasty, G. macrophylla Pall. has been recognized as the primary source, historical research has firmly established its origin, and it remains in use today.

Characterized by its pungent, bitter, and neutral taste, G. macrophylla is traditionally used for dispelling wind-dampness, clearing damp-heat, alleviating arthralgia pain, reducing deficiency heat, and treating a variety of conditions including rheumatism, arthralgia, stroke-related hemiplegia, muscle spasms, aching joints, damp-heat jaundice, bone-steaming hot flashes, and infantile malnutrition fever.

Common Names and Preparations

The root drug bears several common names depending on linguistic and geographic context: Qinjiao (秦艽) in Chinese, large-leaf gentian root or large gentian root in English, and Radix Gentianae Macrophyllae in pharmacopoeial Latin. The roots are dug in spring or autumn; after the fibrous root bark has been removed, the roots are cleaned, dried in the sun, and cut into slices. Preparations include traditional water decoctions, dry powder, wine-based extracts for topical application, and modern standardised preparations such as capsules and patent formula granules.

2. Traditional and Historical Use

Ancient Chinese Medical Texts

Gentianae Macrophyllae Radix (GMR; Qin-Jiao) is used in traditional Chinese medicine to dispel wind-dampness, clear damp-heat, reduce false heat, and relieve arthralgia and pain. Its use dates back to the Shennong Bencao Jing (Divine Farmer's Materia Medica, 1st–2nd century AD), where it was classified as a 'middle-grade' herb known for treating 'pathogenic cold-heat factors, wind-damp joint pain, and arthralgia.' This Han Dynasty text established the herb's foundational medicinal identity.

Documentation continued across subsequent Chinese dynasties. Qinjiao has been described and recorded in several Chinese Medicine monographs including Shen Nong's Herbal Classic (Han Dynasty, 神农本草经), Commentaries on the Illustrations (Song Dynasty, 图经本草), An Illustrated Book on Plants (Qing Dynasty, 植物名实图考), and especially the Compendium of Materia Medica (Ming Dynasty, 本草纲目), which described Qinjiao as a middle-grade medicine. Li Shizhen's Bencao Gangmu (Compendium of Materia Medica), written during the Ming Dynasty, specifically highlights GMR's effectiveness in relieving joint obstructions, reinforcing its traditional use in treating joint pain syndromes.

Radix Gentianae Macrophyllae has medically been used for the treatment of various diseases such as arthritis, stroke, facial paralysis, and scapulohumeral periarthritis in China since ancient times.

TCM Functional Theory

In TCM theory, the herb is characterised as bitter, pungent, and slightly cold in nature, and its actions are associated with the stomach, liver, and gallbladder meridians. Classical texts attributed to it the capacities to dispel wind and dampness, clear damp-heat jaundice, alleviate arthralgia pain, reduce yin-deficiency heat, and act as a mild laxative. In traditional Chinese medicine, G. macrophylla (qin jiao) is considered to have a neutral nature and a bitter, pungent taste; it is associated with the liver, stomach, and gallbladder; and is used as a tonic for the digestive system and to treat arthritis, chronic low-grade fever, jaundice, hepatitis, and constipation.

The herb's traditional functional value was also recognised in conditions described as "bone-steaming fever" (hectic or low-grade fever arising from yin deficiency), damp-heat jaundice, infantile nutritional fever, and musculoskeletal spasm. For over 2000 years, G. macrophylla has been prescribed for treating pain and inflammatory conditions.

Classical Prescriptions and Combinations

In TCM systems, the clinical application of GMR exhibits three distinct characteristics: diversity in formula combinations, specificity in processing methods, and clarity in clinical symptom indications. The classical prescriptions using GMR as the monarch drug primarily include Da Qinjiao decoction (DQJD), Qinjiao Biejia powder (QBP), Qinjiao Cangzhu decoction (QCD), and Duhuo Jisheng decoction (DJD).

Root and leaves of G. scabra and Gentiana macrophylla have been used in Chinese herbalism for over 2000 years as an excellent tonic for the digestive system, acting on the stomach, liver, and gallbladder. In traditional formulas, G. macrophylla was often combined with other herbs depending on the symptom pattern: for wind-damp obstruction with heat signs, it was used with Tetrandra root (Fangji) and Honeysuckle stem (Rendongteng); for cold-type pain, it was combined with Notopterygium root (Qianghuo) and Prepared Aconite root (Fuzi); and for damp-heat jaundice, it was paired with Oriental wormwood (Yinchenhao) and Capejasmine (Zhizi).

Tibetan, Mongolian, and Other Traditions

The roots of the perennial herb Gentiana macrophylla Pall. (Qinjiao) have been used for centuries to treat systemic lupus erythematosus (SLE). The roots of Gentiana macrophylla, known as Qinjiao, have been used for centuries to treat systemic lupus erythematosus (SLE). In broader Gentiana ethnopharmacology, traditional medicine texts describe Gentiana preparations as effective for treatment of disorders such as menstrual over-bleeding, conjunctivitis, vitiligo, animal venom poisoning, injuries, infected wounds, and pain and swelling of the liver, spleen, and stomach, as well as sprains of muscles.

3. Key Constituents and Active Compounds

Overall Phytochemical Profile

In total, 248 compounds have been identified in GMR and related plants, including cycloeneether terpene glycosides (29.44%), triterpenoids (11.29%), lignans (2.82%), flavonoids (17.34%), alkaloids (5.24%), and phenolic acids/benzoic acids (8.47%). An earlier review noted a slightly lower total: so far 166 compounds have been isolated and identified from Qinjiao plants. GMR mainly contains iridoids and secoiridoids, in addition to triterpenoids, flavonoids, lignans, steroids, alkaloids, and other chemical components; iridoids and secoiridoids are the main active ingredients of GMR.

Primary Iridoid and Secoiridoid Glycosides

Phytochemical studies have indicated that G. macrophylla contains various compounds such as iridoids, triterpenes, flavonoids, sterols, and alkaloids. Of these, derivatives of iridoids and triterpenes are the predominant bioactive ingredients responsible for the biological activities of Qinjiao. For instance, gentiopicroside and loganic acid are two secoiridoid glucosides in G. macrophylla with powerful anti-inflammatory and osteoprotective effects.

The principal identified secoiridoid and iridoid compounds include:

• Gentiopicroside (gentiopicrin) — the most abundant and pharmacologically studied secoiridoid glycoside. Iridoids are the main active components of Gentianae macrophyllae Radix, and among them, gentiopicroside has the highest content.
• Loganic acid — a second major quality marker. In the Chinese Pharmacopoeia (2015 edition), gentiopicroside and loganic acid are the index compounds for content determination for quality control of Gentianae macrophyllae Radix.
• Sweroside — a secoiridoid glycoside present in the water-soluble fraction. HPLC analysis showed a high concentration of gentiopicroside (588.48 μg/mL) in the ethanol fraction of the sonication extract, with loganic acid (283.58 μg/mL) and sweroside (9.49 μg/mL) in the water fraction.
• Swertiamarine (swertiamarin) — an additional iridoid glycoside present in significant quantities. Loganic acid, gentiopicroside, 6′-O-β-d-glucosylgentiopicroside, swertiamarine, and sweroside are reported to have various excellent activities, and have been recorded as quality markers in the Chinese Pharmacopoeia (2020 edition).
• 6′-O-β-d-Glucosylgentiopicroside — a further secoiridoid marker compound relevant to quality control.

The total content of gentiopicroside and loganic acid in qualified Gentiana macrophylla samples should be greater than 2.5%, according to Chinese Pharmacopoeia standards.

Triterpenoids

Triterpenoid compounds, including soyasapogenol B and related oleanane- and lupane-type structures, have been identified among the secondary metabolites. Novel compounds including gentimilegenins A and B, hydroxyl-swerimuslactone derivatives, hydroxy-roburic acid methyl ester, hydroxyl-gentioxepine, and N-acyl anthranilic acid derivatives, together with 40 known compounds, have been isolated from the roots of Gentiana macrophylla Pall.

Flavonoids

Flavonoids constitute a notable proportion of the total phytochemical profile. Phytochemical studies reveal that the therapeutic properties of Gentiana are attributed to secondary metabolites, including iridoids, flavonoids, and xanthones. Luteoloside (luteolin-7-O-glucoside) has been identified as one of the more pharmacologically active flavonoids isolated from GMR.

Alkaloids and Antifungal Compounds

Four antifungal bisphosphocholines — irlbacholine and three new analogues, gentianalines A–C — were identified from G. crassicaulis by a bioassay-guided fractionation approach. Subsequent chemical analysis of Qinjiao samples showed that bisphosphocholines were present in all four Gentiana species, with irlbacholine as the major compound ranging from 2.0 to 6.2 mg per gram of dried material. Irlbacholine exhibited potent in vitro antifungal activity against Cryptococcus neoformans, Aspergillus fumigatus, Candida albicans, and Candida glabrata.

4. Established Mechanisms of Action

NF-κB and MAPK Inflammatory Signalling

The anti-inflammatory activity of G. macrophylla is predominantly attributed to gentiopicroside's multi-target interference with key inflammatory cascades. The anti-inflammatory effects of Gentianae Radix primarily target the NF-κB (Nuclear Factor κB) signalling axis. Experimental evidence confirms that the active component gentiopicroside inhibits IκB kinase β (IKKβ) phosphorylation, blocks NF-κB nuclear translocation, and subsequently downregulates key inflammatory mediators such as COX-2, TNF-α, and IL-6. Gentiopicroside directly inhibits the phosphorylation of IKKβ, preventing degradation of IκB and subsequent nuclear translocation of the NF-κB p65 subunit. Concurrently, gentiopicroside suppresses the activation of JNK and p38 within the MAPK pathway, further reducing the production of pro-inflammatory cytokines.

NLRP3 Inflammasome Suppression

Gentiopicroside was able to inhibit ROS-NF-κB activation and to disrupt NLRP3 inflammasome assembly, thereby reducing IL-1β secretion. Rheumatoid arthritis is among the most prevalent forms of autoimmunity, and gentiopicroside is an iridoid glucoside derived from Gentiana macrophylla Pall. which is used in traditional Chinese medicine to treat RA.

Gastrointestinal Prokinetic Mechanisms

Gentiopicroside accelerated gastric emptying, strengthened intestinal motility, and increased the secretion of gastric acid. The prokinetic activity of gentiopicroside from Gentiana macrophylla Pall. is widely used to strengthen gastric motility in clinical settings; gastrointestinal motility disorder in rat models is induced by stress stimulation, and treated rats showed improved gastrointestinal hormonal profiles. Specifically, an isolated guinea pig ileum was applied to evaluate the influences on muscarinic (M-R), histamine (H1-R), serotonin (5-HT4-R), and dopamine (D-R) receptors in vitro, and gentiopicroside increased gastric emptying and intestinal propelling obviously.

Hepatoprotective Mechanisms

Gentiana macrophylla could decrease the activities of ALT and AST in the serum of CCl4-induced acute liver injury mice, as well as MDA in the liver, and it also enhances the activity of SOD. Following the administration of this extract, the damaged hepatic tissue structure was restored, and the amount of collagen deposition decreased. The facilitation of drug metabolism causes hepatoprotective effects, amelioration of mitochondrial dysfunction, and a reduction in oxidative stress.

Bone Metabolism and Anti-Osteoporotic Mechanisms

Gentiopicroside may be useful in osteoporosis treatment through its impact on receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclastogenesis; gentiopicroside inhibited the activation of JNK and NF-κB signalling pathways, thereby preventing osteoclastogenesis. Furthermore, in vitro results showed that gentiopicroside promoted the activity of alkaline phosphatase, increased the calcified nodules in bone mesenchymal stem cells (BMSCs), and up-regulated osteogenic factors (Runx2, OSX, OCN, OPN, and BMP2).

Neuroprotective Mechanisms

Gentiopicroside is also being investigated for its potential to reduce neurotoxicity by modulating astrocyte-mediated inflammation. Gentiopicroside reduced the release of TNF-α, IL-1β, nitric oxide (NO), and PGE, as well as the expression of iNOS and COX-2 in astrocytes. It also suppressed NF-κB translocation and JNK/SAPK MAPK phosphorylation, while having minimal effect on p-p38 levels.

Antifibrotic and Pulmonary Mechanisms

Gentiopicroside downregulates the expression of TGF-β1 and connective tissue growth factor (CTGF) in the lungs and also inhibits the epithelial-mesenchymal transition of A549 cells induced by TGF-β1.

5. Scientific Evidence by Area of Use

5.1 Musculoskeletal Inflammation and Rheumatoid Arthritis

Evidence type: Predominantly preclinical (in vitro and animal models); some clinical narrative review reports.

Acute treatment of rheumatoid rats with an extract from the roots of Gentiana macrophylla produced a significant inhibitory effect on rheumatoid arthritis. When rats were administered the extract orally at a daily dose of 100 mg/kg body weight, the prostaglandin E₂ (PGE₂) levels in the inflammatory tissues, sole thickness, and ankle circumferences of feet were significantly decreased. The anti-inflammatory activity observed in Gentiana macrophylla is comparable to that observed in prednisone. This is a rodent (animal) model study; there are no published randomised controlled trials in humans for G. macrophylla as a single agent for RA.

Gentiopicroside was able to significantly reduce the swelling of joints and arthritic index scores, with corresponding reductions in synovial inflammatory cell infiltration, synovial hyperplasia, and bone erosion in treated adjuvant-induced arthritis (AIA) rats. At the cellular level, gentiopicroside has been reported to beneficially affect rheumatoid arthritis by suppressing the ROS-NF-κB-NLRP3 axis, and experimental studies have confirmed the anti-rheumatic effects of gentiopicroside both in vitro (using TNF-α-stimulated human rheumatoid arthritis fibroblast-like synoviocytes) and in vivo in adjuvant-induced arthritis rat models.

In a study investigating GEN's anti-rheumatoid arthritic activities in a model of rheumatoid arthritis, in vivo male C57BL/6J mice were injected with chicken type II collagen to induce the collagen-induced arthritis (CIA) model, and in vitro research was performed in rheumatoid fibroblast-like synoviocytes (FLS). GEN treatment could not only reduce synovitis and inhibit the proliferation of RA FLS but also relieve cartilage damage in the CIA model. Moreover, GEN treatment lessened the pain behaviours of CIA mice.

In clinical practice, GMR is mainly used to treat rheumatoid arthritis, ulcerative colitis, stroke, and other related diseases with good therapeutic effects, according to a comprehensive review; however, the cited clinical evidence is drawn largely from TCM clinical reports and combination formula studies rather than large-scale, double-blind placebo-controlled trials. The overall evidence base for G. macrophylla in RA is considered promising but preliminary, resting heavily on preclinical data.

5.2 Gastrointestinal Function and Gastroprotection

Evidence type: Preclinical (rodent and guinea pig models); limited commercial clinical reports.

Jiaolong capsule (a commercial product of gentiopicroside, 480 mg/day) has been reported to improve constipation, functional dyspepsia, abdominal distension, and reflux esophagitis. Jiaolong capsule showed more improvement effect than domperidone on functional dyspeptics. These reports originate from Chinese clinical observations referenced in peer-reviewed research, though formal randomised trial design specifics are not extensively detailed in the available literature.

Gentiopicroside treatment significantly attenuated damage to the intestinal mucosa and symptoms including weight loss and diarrhea. This was associated with decreased mRNA expression of inflammatory markers, as well as TNF-α, IL-1β, IL-6, and a reduction in the overexpression of COX-2 and iNOS proteins in the colon.

Gastroprotective activity is supported by preclinical evidence: gentiopicroside can reduce contractions induced by histamine, acetylcholine, KCl, and BaCl₂. In pylorus-ligated rats, gentian root methanol extract suppresses the secretion of gastric juice and total acid output. This extract is also active against acute gastric ulcers induced by aspirin and gastric mucosal injury induced by ethanol. Clinical confirmation in human trials is limited.

5.3 Hepatoprotection

Evidence type: Preclinical (animal models, cell lines); one in vivo murine SLE model study.

Sweroside, one of the iridoid constituents, reduces the level of ALT in patients who suffer from hepatitis. Methanol extracts of Gentiana species containing high levels of sweroside and gentiopicroside are useful in the treatment of liver injuries triggered by carbon tetrachloride, normalising elevated serum levels of AST, ALT, and ALP.

In a murine SLE model: this study investigated whether GM exhibits anti-apoptotic effects, focusing on the left ventricle of NZB/W F1 mice fed a high-cholesterol diet. The morphology and apoptotic status of ventricular tissues were determined by microscopy and TUNEL assay. Levels of apoptotic biomarkers were determined by immunoblotting. The results revealed that GM significantly reduced the cholesterol-aggravated apoptosis of LV in NZB/W F1 mice by suppressing both intrinsic and extrinsic apoptotic pathways. Additionally, GM significantly increased the cardiac insulin-like growth factor (IGF)-1 survival signalling and anti-apoptotic proteins in LV tissues, and is considered to be beneficial in alleviating cholesterol-aggravated cardiac damage in SLE. This is an animal study and cannot be directly extrapolated to human outcomes.

Many groups have chemically investigated roots of Gentiana macrophylla Pall., a traditional Chinese drug with a long history of use in treating jaundice, hepatitis, constipation, pains, and rheumatism. Although most of the constituents of GM have been identified, information about the functional constituents and their mechanisms is limited, especially in relation to autoimmune diseases.

5.4 Bone and Skeletal Health (Osteoporosis)

Evidence type: Preclinical (in vitro, ovariectomised mouse model).

Extracts of Gentiana macrophylla Pall., rich in sweroside, have exhibited potent antioxidant activity in DPPH, NBT, and FRAP assays, with IC₅₀ values of 275, 262, and 180 μg/mL, respectively, in a concentration-dependent manner. These extracts also reduced serum ALP levels, decreased urinary calcium excretion, and increased serum calcium concentrations, suggesting a protective effect against osteoporosis mediated by antioxidant mechanisms.

In vitro, bone mesenchymal stem cells (BMSCs) were exposed to gentiopicroside at different doses for 2 weeks, whereas in vivo, ovariectomized osteoporosis was established in mice and the therapeutic effect was evaluated for 3 months. In vitro results showed that gentiopicroside promoted the activity of alkaline phosphatase, increased the calcified nodules in BMSCs, and up-regulated the osteogenic factors Runx2, OSX, OCN, OPN, and BMP2. No human clinical trials specifically examining G. macrophylla or its isolated constituents for osteoporosis in humans were identified in the peer-reviewed literature accessed for this article.

5.5 Autoimmune Conditions (Systemic Lupus Erythematosus)

Evidence type: Animal model (NZB/W F1 lupus-prone mice).

The roots of Gentiana macrophylla, known as Qinjiao, have been used for centuries to treat systemic lupus erythematosus (SLE). Gentiana macrophylla shows potential in alleviating cholesterol-induced cardiac damage in SLE, offering an alternative treatment for SLE patients with cardiac abnormalities. Evidence is confined to animal models; no randomised human studies in SLE were identified in the peer-reviewed literature.

5.6 Antioxidant and Antimicrobial Activity

Evidence type: In vitro.

The root extract (sonication extraction) of G. macrophylla Pall. demonstrated dose-dependent antioxidant activity (DPPH, NBT, FRAP assays) and outstanding antibacterial activities against Escherichia coli and Staphylococcus aureus at lower concentrations. These are in vitro results and have not been translated to clinical studies in humans.

5.7 Neuroprotection and Antidepressant Potential

Evidence type: In vitro and animal models.

Gentiopicroside has been shown to possess analgesic, anti-inflammatory, anti-cancer, lipid-regulating, and antidepressant properties based on preclinical research. The antidepressant activity has been reported in animal behavioural models, and the analgesic effects have been demonstrated in standard rodent pain tests. These encompass a wide range of effects including hepatoprotective, anti-inflammatory, antifibrotic, antioxidant, analgesic, antitumour, and immunomodulatory properties, as described in a focused review of gentiopicroside's regulatory mechanisms. Human clinical data for neuroprotective or antidepressant endpoints are not available from the peer-reviewed sources identified.

5.8 Immunomodulation

Bioactive compounds from the Gentiana genus exhibit diverse pharmacological properties through their effects on apoptosis, autophagy, inflammation, NF-κB signalling, MAPK pathways, growth factors, and cytochrome P450 enzymes. Modern pharmacological studies have shown that GMR has pharmacological effects including anti-inflammatory, anti-tumour, hepatoprotective, immunomodulatory, and cardioprotective activities. The immunomodulatory evidence is exclusively preclinical; no clinical immunomodulatory trials for G. macrophylla as a single agent have been identified.

6. Body Systems and Health Areas of Association

Based on the totality of traditional use and pharmacological research, G. macrophylla is associated with the following body systems:

• Musculoskeletal system: Rheumatoid arthritis, osteoarthritis, joint inflammation, bone loss, muscle spasm, scapulohumeral periarthritis, stroke-related musculoskeletal sequelae
• Hepatobiliary system: Hepatoprotection, jaundice, hepatitis, damp-heat liver conditions
• Gastrointestinal system: Gastric motility, gastroprotection, ulceration, functional dyspepsia, constipation, ulcerative colitis
• Immune and autoimmune system: SLE, RA, inflammasome modulation
• Skeletal/endocrine (bone): Osteoporosis prevention, osteoclast suppression, osteoblast promotion
• Nervous system: Analgesic activity, neuroprotection, antidepressant effects (preclinical)
• Cardiovascular system: Cardiac protection in lupus-associated pathology (preclinical)

The medicinal uses of substances extracted from gentian herbs, along with the pharmacological potential of key bioactive compounds, show promise in treating various conditions including liver disorders, inflammatory disorders, cardiovascular disorders, osteoporosis, thromboembolic disorders, atherosclerosis, and oxidative stress-related damage.

7. Dosage Forms and Reported Dosages

Traditional Decoction

The traditional dosage of Qinjiao is 5–10 g, decocted in water for an oral dose. This is the classical TCM preparation, produced by simmering the dried, sliced root in water.

Powder (Internal and External Use)

Powder form has been historically used both internally and externally. For internal use, doses have typically been 1–3 grams in powder form. Externally, powder can be mixed with water, a suitable decoction, wine, or alcohol for topical application, as documented in classical texts including the Ben Cao Gang Mu.

Standardised Extract and Commercial Preparations

Jiaolong capsule (a commercial product of gentiopicroside) at 480 mg/day has been used to improve constipation, functional dyspepsia, abdominal distension, and reflux esophagitis.

Doses Used in Preclinical Studies

In the rat rheumatoid arthritis inhibition study, G. macrophylla extract was administered orally at a daily dose of 100 mg/kg body weight. In the AIA rat model, Gent at 200 mg/kg was used to assess effects on thymus index. In pharmacokinetic studies, oral administration of total iridoid glucosides at 520 mg/kg (equivalent to 240 mg/kg of gentiopicroside) was investigated. These are animal study doses and cannot be directly applied to human dosing.

Classical Formula Combinations

In TCM systems, the classical prescriptions using GMR as the monarch drug primarily include Da Qinjiao decoction (DQJD), Qinjiao Biejia powder (QBP), Qinjiao Cangzhu decoction (QCD), and Duhuo Jisheng decoction (DJD). In these polyherbal formulas, GMR is typically used as one of multiple herbs and the overall formula dose varies by indication and practitioner.

8. Safety Considerations and Interactions

General Safety in Preclinical Studies

Amarogentin at a dose of 1000 mg/kg did not produce any signs of toxicity for up to 14 days in C57BL/6 mice. Gentiana macrophylla Pall. root extract caused no mortality and abnormal performance at the dose of 500 mg/kg in Kunming mice. Crude extracts of Gentiana show no apparent toxicity in in vivo and in vitro studies. These findings are based on animal studies and do not replace formal human safety evaluation.

Contraindications in TCM

This herb is contraindicated for a person with a weak constitution or in cases suffering from diarrhea. In traditional TCM classification, its slightly cold and bitter nature is considered inappropriate where there is constitutional cold-deficiency of the stomach or spleen.

Adulteration and Quality Control Concerns

As a traditional Chinese medicinal material, GMR faces significant challenges in quality control due to frequent adulteration and substitution. To ensure its quality, the Chinese Pharmacopoeia recommends that, in addition to the HPLC method, morphological, microscopic, and thin-layer chromatography identification techniques should also be performed. The total content of gentiopicroside and loganic acid in qualified Gentiana macrophylla samples should be greater than 2.5%. Substandard or adulterated material could pose undetermined risks.

Lack of Formal Human Toxicological Data

Although identification of compounds from Qinjiao and demonstration of medicinal uses in vitro and in vivo have been carried out, various other studies should deserve more attention. More efforts should be concentrated on the underlying mechanisms of their beneficial bioactivities. The proper toxic evaluation is indispensable to guarantee the safety, efficacy, and eligibility for medical use.

Limited Clinical Research

Clinical research on the therapeutic applications of Gentiana remains limited. The absence of large-scale human pharmacovigilance data means the full safety profile — including potential drug interactions, effects in pregnancy, and chronic use toxicity — has not been systematically characterised in human populations. Gastric irritation has been noted as a possibility with bitter-principle-containing Gentiana preparations: in a few sensitive people, gentiana can cause stomach irritation and headache.

Gastric Ulcer Precaution

German health authorities recommend that gentiana not be used by people who have stomach (gastric) or intestinal (duodenal) ulcers. This recommendation pertains specifically to Gentiana root preparations and reflects the stimulating effect of bitter principles on gastric acid secretion.

Conservation Status

Beyond pharmacological safety, a supply-chain consideration exists: overexploitation driven by economic interests and the lack of effective protective measures has resulted in a dramatic decline of wild G. macrophylla plants in recent years, and G. macrophylla is now listed on the National Key of Protected Wild Herbs in China. The increasing demand for this material has led to the widespread cultivation of the plant; however, differences in chemical constituents between wild and cultivated G. macrophylla remain under investigation.

References

• Zhang X, et al. "Botany, traditional use, phytochemistry, pharmacology, quality control, and authentication of Radix Gentianae Macrophyllae — A traditional medicine: A review." Phytomedicine. 2018. PubMed PMID: 30097114
• Gentianae Macrophyllae Radix (Qin-Jiao): A systematic review of ethnopharmacology, phytochemistry, pharmacology, clinical application and quality control. Journal of Ethnopharmacology. 2025. ScienceDirect
• De novo genome assembly of Gentiana macrophylla provides insights into genomic evolution and biosynthesis of iridoids. PMC9724787
• Study on effects of sweating treatment and different drying methods on the quality of Gentianae macrophyllae Radix. PMC8102551
• Medicinal, biological and phytochemical properties of Gentiana species. PMC5634738
• The Root Extract of Gentiana macrophylla Pall. Alleviates Cardiac Apoptosis in Lupus Prone Mice. PMC4436133
• Anti-Rheumatic Properties of Gentiopicroside Are Associated With Suppression of ROS-NF-κB-NLRP3 Axis in Fibroblast-Like Synoviocytes and NF-κB Pathway in Adjuvant-Induced Arthritis. Frontiers in Pharmacology. 2020
• Inhibitory effects of the Gentiana macrophylla (Gentianaceae) extract on rheumatoid arthritis of rats. PubMed PMID: 15374610
• An integrated strategy for quality control of the multi-origins herb medicine of Gentianae Macrophyllae Radix. PMC10018649
• Gentianaceae Family — Derived Bioactive Compounds — Therapeutic Values and Supporting Role in Inflammation and Detoxification. PMC12389160
• Multidimensional comparative analysis of wild and cultivated Gentiana macrophylla based on electronic intelligent sensory technology and chemical composition. PMC11874731
• Seven new chemical constituents from the roots of Gentiana macrophylla Pall. PubMed PMID: 31927012
• Attenuation of stress-induced gastrointestinal motility disorder by gentiopicroside, from Gentiana macrophylla Pall. PubMed PMID: 25936770
• Gentiopicroside promotes the osteogenesis of bone mesenchymal stem cells by modulation of β-catenin-BMP2 signalling pathway. PMC8642693
• Sweroside: unveiling broad therapeutic potential — from mechanistic insights to clinical potential. Frontiers in Pharmacology. 2025
• The chemical structure, pharmacological activity, and clinical progress of Gentianae Radix et Rhizoma. Frontiers in Pharmacology. 2025
• Terpenoid Glucosides from Gentiana macrophylla That Attenuate TNF-α Induced Pulmonary Inflammation in A549 Cells. PubMed PMID: 37764389
• A comprehensive review of phytochemistry, pharmacology and clinical application of Gentianae Macrophyllae Radix. Natural Product Research. 2024
• Regulatory mechanisms of Gentiopicroside on human diseases: a brief review. PubMed PMID: 37632552
• Genus Gentiana: A review on phytochemistry, pharmacology and molecular mechanism. Journal of Ethnopharmacology. 2021. ScienceDirect